Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell 6.25% in its Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market volatility kept investors cautious toward new listings. Sign up here. Reporting by Pragyan Kalita in Bengaluru; Editing by Sahal Muhammed Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut Februa ...